Cervical Cancer
Conditions
Keywords
Stage Ib2-early IIb of cervical cancer, Neoadjuvant chemotherapy, Cisplatin plus gemcitabine, Radical hysterectomy with pelvic lymphadenectomy, Quality of life, Stage Ib2-IIb of cervical cancer patients
Brief summary
The purpose of this study is: * to compare the effectiveness between the new strategy of treatment (given cis-platinum plus gemcitabine-neoadjuvant chemotherapy followed by surgery),and standard treatment (given cis-platinum/carboplatin during radiation-concurrent chemoradiation)in specific group of cervical cancer patients (stage Ib2-early IIb) * to evaluate quality of life in both group of patients(standard treatment vs.experimental group)
Detailed description
According to FIGO classification of cervical cancer, stage Ib2 was classified as clinically visible lesion more than 4.0 cm in greatest dimension and stage IIb was classified tumor invades parametrium must not to pelvic wall. These were the common stages in Thai cervical cancer patients,and made a troublesome effect to Thai women. According to this study,stage early IIb with 1/3 of parametrium involvement. Mostly these two stage was treated with concurrent chemoradiation, challenging the possibility of late sequelae of radiation effect. This specific group of patients can be avoid the referred side effect by using neoadjuvant chemotherapy followed by radical hysterectomy with pelvic lymphadenectomy and para-aortic node sampling in operable cases (at least partial response- PR) and concurrent chemoradiation (CCR) in inoperable cases (less than PR). Due to high risk type of these subspecific group, combination chemotherapy instead of single chemotherapy was used as CCR. However in operable cases with identified poor prognostic factor should be receive post operative radiation as the usual manner.
Interventions
Cisplatin 50 mg/m2 (in the vein)on day 1 of each 23 day cycle plus gemcitabine 1000 mg/m2 (in the vein) on day 1 and day 8, for 3 cycles: until progression or unacceptable toxicity develops.
Sponsors
National Research Council of Thailand
Clinical Research Collaborative Network
Thai Gynecologic Oncology Collaborative Group
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* Cervical cancer patients with FIGO stage Ib2-early IIb * Pathological proven squamous cell carcinoma or adenocarcinoma or adenosquamous cell carcinoma * ECOG performance status 0-1 * No previous treatment for cervical cancer * Acceptable hematological,renal,liver function
Exclusion criteria
* Previous history of cancer * Underlying disease not fit for surgery * Psychological problem * Obvious pelvic/para-aortic node involvement * Pregnancy * HIV positive * History of bowel obstruction
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival comparison between experimental treatment group and standard treatment group | 9 Years |
Secondary
| Measure | Time frame |
|---|---|
| Comparing disease free survival between experimental treatment group and standard treatment group | 9 years |
Countries
Thailand
Contacts
Primary ContactSaibua B. Chichareon, MD.
Backup ContactChutaporn - Dampan, BSc
Outcome results
None listed